Published in Eur J Med Chem on March 01, 2002
The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci (2009) 1.17
Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors. J Mol Model (2006) 0.88
Docking of 1,4-benzodiazepines in the alpha1/gamma2 GABA(A) receptor modulator site. Mol Pharmacol (2009) 0.85
Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg Med Chem (2002) 2.03
Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem (2005) 1.60
Antihyperalgesic effects of a novel muscarinic agonist (LASSBio-873) in spinal nerve ligation in rats. Clin Exp Pharmacol Physiol (2013) 1.39
Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. J Pharm Pharmacol (2008) 1.30
Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem (2007) 1.28
From nature to drug discovery: the indole scaffold as a 'privileged structure'. Mini Rev Med Chem (2009) 1.17
Design, synthesis, and pharmacological evaluation of new neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives with in vivo hypnotic and analgesic profile. Bioorg Med Chem (2005) 1.17
Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives. Eur J Med Chem (2009) 1.12
Further bioactive piperidine alkaloids from the flowers and green fruits of Cassia spectabilis. J Nat Prod (2004) 1.06
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorg Med Chem (2010) 1.03
Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorg Med Chem (2005) 1.02
Design and synthesis of 3,4-methylenedioxy-6-nitrophenoxyacetylhydrazone derivatives obtained from natural safrole: new lead-agents with analgesic and antipyretic properties. Bioorg Med Chem (2006) 1.02
New class of potent antinociceptive and antiplatelet 10H-phenothiazine-1-acylhydrazone derivatives. Bioorg Med Chem (2004) 1.00
Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands. Bioorg Med Chem (2003) 0.99
Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem (2007) 0.98
Synthesis and anti-platelet activity of novel arylsulfonate--acylhydrazone derivatives, designed as antithrombotic candidates. Eur J Med Chem (2007) 0.98
Construction of 4D-QSAR models for use in the design of novel p38-MAPK inhibitors. J Comput Aided Mol Des (2005) 0.97
Synthesis and biological evaluation of new imidazo[1,2-a]pyridine derivatives designed as mefloquine analogues. Farmaco (2002) 0.96
Docking of the alkaloid geissospermine into acetylcholinesterase: a natural scaffold targeting the treatment of Alzheimer's disease. J Mol Model (2010) 0.95
The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease. CNS Neurol Disord Drug Targets (2011) 0.93
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors. J Med Chem (2012) 0.92
Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives. Bioorg Med Chem (2003) 0.91
Discovery of novel orally active anti-inflammatory N-phenylpyrazolyl-N-glycinyl-hydrazone derivatives that inhibit TNF-α production. PLoS One (2012) 0.90
Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE). Eur J Med Chem (2010) 0.90
Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates. Eur J Med Chem (2009) 0.89
Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorg Med Chem (2008) 0.89
Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors. J Mol Model (2006) 0.88
The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease. CNS Neurol Disord Drug Targets (2011) 0.86
Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorg Med Chem Lett (2005) 0.86
Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors. Bioorg Med Chem (2007) 0.85
Structure-activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies. J Med Chem (2002) 0.85
Hologram QSAR models of 4-[(diethylamino)methyl]-phenol inhibitors of acetyl/butyrylcholinesterase enzymes as potential anti-Alzheimer agents. Molecules (2012) 0.84
Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg Med Chem (2008) 0.84
Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. Eur J Pharmacol (2010) 0.83
Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline-induced pulmonary hypertension in rats. Br J Pharmacol (2013) 0.83
New isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates. Eur J Med Chem (2002) 0.83
New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors. Mini Rev Med Chem (2005) 0.83
Application of 4D-QSAR studies to a series of raloxifene analogs and design of potential selective estrogen receptor modulators. Molecules (2012) 0.83
3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes. Eur J Med Chem (2009) 0.82
New selective acetylcholinesterase inhibitors designed from natural piperidine alkaloids. Bioorg Med Chem (2005) 0.81
2-Acetylpyridine thiosemicarbazones: cytotoxic activity in nanomolar doses against malignant gliomas. Eur J Med Chem (2010) 0.81
Pharmacological characterization of (3-thienylidene)-3,4-methylenedioxybenzoylhydrazide: a novel muscarinic agonist with antihypertensive profile. Am J Hypertens (2009) 0.81
Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of IκB kinase-β. Eur J Med Chem (2011) 0.81
Residue-ligand interaction energy (ReLIE) on a receptor-dependent 3D-QSAR analysis of S- and NH-DABOs as non-nucleoside reverse transcriptase inhibitors. Molecules (2012) 0.81
Synthesis and analgesic profile of conformationally constrained N-acylhydrazone analogues: discovery of novel N-arylideneamino quinazolin-4(3H)-one compounds derived from natural safrole. Bioorg Med Chem (2009) 0.80
Synthesis, biological evaluation, and structure-activity relationship of clonazepam, meclonazepam, and 1,4-benzodiazepine compounds with schistosomicidal activity. Chem Biol Drug Des (2012) 0.80
Docking, synthesis and anti-diabetic activity of novel sulfonylhydrazone derivatives designed as PPAR-gamma agonists. Curr Top Med Chem (2012) 0.80
Analgesic and anti-inflammatory activities of salicylaldehyde 2-chlorobenzoyl hydrazone (H(2)LASSBio-466), salicylaldehyde 4-chlorobenzoyl hydrazone (H(2)LASSBio-1064) and their zinc(II) complexes. Molecules (2011) 0.80
Antinociceptive profile of (-)-spectaline: a piperidine alkaloid from Cassia leptophylla. Planta Med (2003) 0.79
The molecular basis for coxib inhibition of p38alpha MAP kinase. Bioorg Med Chem Lett (2005) 0.79
Characterization of amide bond conformers for a novel heterocyclic template of N-acylhydrazone derivatives. Molecules (2013) 0.79
Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFalpha modulators. Bioorg Med Chem (2006) 0.79
Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorg Med Chem (2012) 0.79
Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases. J Biomol Struct Dyn (2004) 0.78
LASSBio 596 per os avoids pulmonary and hepatic inflammation induced by microcystin-LR. Toxicon (2011) 0.78
A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. Bioorg Med Chem (2004) 0.78
Potential inhibitory effect of LASSBio-596, a new thalidomide hybrid, on inflammatory corneal angiogenesis in rabbits. Ophthalmic Res (2012) 0.78
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorg Med Chem (2010) 0.78
Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. Eur J Med Chem (2012) 0.78
New oxidovanadium(IV) N-acylhydrazone complexes: promising antileishmanial and antitrypanosomal agents. Eur J Med Chem (2012) 0.78
Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-adrenergic receptor blocking properties. Eur J Med Chem (2011) 0.78
A proposed molecular basis for the selective resveratrol inhibition of the PGHS-1 peroxidase activity. Bioorg Med Chem (2005) 0.78
Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. Bioorg Med Chem Lett (2010) 0.78
Thienylhydrazone derivative increases sarcoplasmic reticulum Ca2+ release in mammalian skeletal muscle. Eur J Pharmacol (2003) 0.78
Can LASSBio 596 and dexamethasone treat acute lung and liver inflammation induced by microcystin-LR? Toxicon (2010) 0.77
Design, synthesis and analgesic properties of novel conformationally-restricted N-acylhydrazones (NAH). Bioorg Med Chem Lett (2009) 0.77
MAOS and medicinal chemistry: some important examples from the last years. Molecules (2011) 0.77
Molecular docking study and development of an empirical binding free energy model for phosphodiesterase 4 inhibitors. Bioorg Med Chem (2006) 0.77
Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacol Rep (2011) 0.77
Synthesis and pharmacological evaluation of novel antinociceptive N-substituted-phenylimidazolyl-4-acylhydrazone derivatives. Farmaco (2002) 0.77
Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. Eur J Med Chem (2013) 0.77
Synthesis and pharmacological evaluation of novel phenyl sulfonamide derivatives designed as modulators of pulmonary inflammatory response. Molecules (2012) 0.77
Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone. J Mol Model (2011) 0.77
Novel phthalimide derivatives, designed as leukotriene D(4) receptor antagonists. Bioorg Med Chem Lett (2002) 0.77
Characterization of the conformational ensemble from bioactive N-acylhydrazone derivatives. J Mol Graph Model (2009) 0.77
Sedation and antinociception induced by a new pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivative (LASSBio-873) is modulated by activation of muscarinic receptors. Pharmacol Biochem Behav (2009) 0.77
Design, synthesis, antinociceptive and anti-inflammatory activities of novel piroxicam analogues. Molecules (2012) 0.77
Molecular dynamics simulations of peptide inhibitors complexed with Trypanosoma cruzi trypanothione reductase. Chem Biol Drug Des (2012) 0.76
Receptor-dependent 4D-QSAR analysis of peptidemimetic inhibitors of Trypanosoma cruzi trypanothione reductase with receptor-based alignment. Chem Biol Drug Des (2012) 0.76
In vitro microsomal hepatic metabolism of antiasthmatic prototype LASSBio-448. Curr Top Med Chem (2014) 0.76
Structural insights into IKKbeta inhibition by natural products staurosporine and quercetin. Bioorg Med Chem Lett (2009) 0.76
Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: orally effective anti-inflammatory drug candidates. Bioorg Med Chem (2008) 0.76
Microwave-assisted synthesis and structure-activity relationships of neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives. Bioorg Med Chem Lett (2009) 0.76
Synthesis, pharmacological evaluation and docking studies of new sulindac analogues. Eur J Med Chem (2008) 0.76
Structure-function inferences based on molecular modeling, sequence-based methods and biological data analysis of snake venom lectins. Toxicon (2006) 0.76
Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. Eur J Med Chem (2012) 0.76
Medicinal chemistry of N-acylhydrazones: new lead-compounds of analgesic, antiinflammatory and antithrombotic drugs. Curr Med Chem (2006) 0.76
New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behav Brain Res (2012) 0.75
Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581. Pharmacol Biochem Behav (2007) 0.75
NSAIDs revisited: putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARgamma). Eur J Med Chem (2007) 0.75
Design of new dopamine D2 receptor ligands: biosynthesis and pharmacological evaluation of the hydroxylated metabolite of LASSBio-581. Bioorg Med Chem Lett (2010) 0.75
Hologram quantitative structure-activity relationship and comparative molecular field analysis studies within a series of tricyclic phthalimide HIV-1 integrase inhibitors. Drug Des Devel Ther (2013) 0.75
CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline. Eur J Pharmacol (2007) 0.75
1-Methyl-7-(4-nitro-phen-yl)-3-phenyl-pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine-6,8(3H,7H)-dione. Acta Crystallogr Sect E Struct Rep Online (2008) 0.75
Synthesis and characterization of the atropisomeric relationships of a substituted N-phenyl-bipyrazole derivative with anti-inflammatory properties. Chirality (2012) 0.75
Novel furfurylidene N-acylhydrazones derived from natural safrole: discovery of LASSBio-1215, a new potent antiplatelet prototype. J Enzyme Inhib Med Chem (2011) 0.75
Thrombin inhibition by novel benzamidine derivatives: a free-energy perturbation study. J Med Chem (2002) 0.75
Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC-MS/MS: application for a pharmacokinetic study. J Pharm Biomed Anal (2011) 0.75
LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model. Behav Pharmacol (2016) 0.75
Structural model of haptoglobin and its complex with the anticoagulant ecotin variants: structure-activity relationship study and analysis of interactions. J Enzyme Inhib Med Chem (2013) 0.75